Yili Chuanning Biotechnology: Capitalizing on AI‑Driven Synthetic Biology Amid Antibiotic Price Pressure
Yili Chuanning Biotechnology’s 2026 earnings reveal short‑term antibiotic pressure but a booming synthetic biology division, AI‑powered fermentation, and strong cash flow poised for growth.
3 minutes to read